BrainsWay Ltd.

NASDAQ:BWAY

Medical - Devices

Healthcare
$8.98 +0.35%

+$0.05 today

Market cap
$352.22M
Beta
0.15
P/E (TTM)
61.7
EPS (TTM)
$0.23
52W Low $5.42High $17.35

Volume 0.15M

Average 0.15M

BWAY EBITDA Margin

EBITDA as a percentage of revenue.

BrainsWay Ltd.NASDAQ: BWAY

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 20.6%

EBITDA Margin was 20.6% in Q1 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 22.4%, up 7.2 pp year over year. Over 3 fiscal years it widened by 64.1 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 16.0% for the fiscal year ending Dec 2026, down from 21.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
20.6%-2.3 pp QoQ
Last fiscal yearDec 2025
21.9%+8.9 pp YoY
LTMMar 2026
22.4%+7.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp-5.3 pp-6.4 pp
1 year+8.9 pp-5.9 pp-14.8 pp
3 years+64.1 pp-3.6 pp-67.7 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
21.9%
Year-over-year change
+8.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BWAY compares with its peers on the latest reported figures

  • BWAY's LTM Mar 2026 EBITDA Margin of 22.4% is the highest of the 4 companies compared; the peer median is -17.0%.
  • Its year-over-year change of +7.2 pp is the 3rd highest of 4, against a peer median of +26.6 pp.
  • Over three fiscal years its change of +64.1 pp compares with a peer median of +68.3 pp.
BWAY Competitors Peer median
EBITDA Margin for BWAY and competitors
Company Period LTM level YoY 3-year change
BWAYBrainsWay Ltd.LTM Mar 202622.4% +7.2 pp+64.1 pp
NPCENeuroPace, Inc.LTM Mar 2026-13.9% +3.1 pp+68.3 pp
STIMNeuronetics, Inc.LTM Mar 2026-17.0% +26.6 pp+30.8 pp
HSDTSolana CompanyLTM Mar 2026-1413.6% +1394.0 pp+1185.2 pp
MOBIMobia Medical, Inc. Common Stock—— ——
Peer median (excluding BWAY) -17.0%+26.6 pp+68.3 pp

Competitors are the stored peer set for BWAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.66M27.18M31.79M41.02M52.23M
Cost of Revenue6.6M7.13M8.31M10.44M12.84M
Gross Profit23.06M20.05M23.48M30.58M39.39M
Gross Margin77.7%73.8%73.9%74.6%75.4%
Research & Development6.39M7.68M6.67M7.19M9.6M
Selling, General & Admin21.66M25.05M21.64M22M25.46M
Operating Expenses28.06M32.73M28.44M29.19M35.06M
Depreciation & Amortization1.69M1.53M1.34M1.77M1.54M
EBITDA(4.67M)(11.45M)(2.56M)5.36M11.46M
EBITDA Margin-15.8%-42.1%-8.1%13.1%21.9%
Operating Income(5M)(12.68M)(4.96M)1.39M4.32M
Operating Margin-16.9%-46.7%-15.6%3.4%8.3%
Interest Income225K1.11M2.17M2.48M5.64M
Interest Expense141K68K298K1.36M2.23M
Other Income / Expenses(1.42M)(351K)1.01M2.07M3.39M
Income Before Tax(6.42M)(13.03M)(3.95M)3.46M7.71M
Pre-Tax Margin-21.6%-48.0%-12.4%8.4%14.8%
Income Tax Expense43K315K251K538K77K
Net Income(6.46M)(13.35M)(4.2M)2.92M7.63M
Net Margin-21.8%-49.1%-13.2%7.1%14.6%
EPS (Basic)(0.21)(0.43)(0.13)0.090.40
EPS (Diluted)(0.21)(0.43)(0.13)0.090.36
Weighted Avg Shares31.15M32.98M33.16M33.97M19.08M
Weighted Avg Shares (Diluted)31.15M32.98M33.16M34.77M21.21M

BrainsWay Ltd.

NASDAQ:BWAY

Intrinsic Alpha fair value

Locked

Current Price

$8.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.